Background. Fluoroquinolone prophylaxis during neutropenia in patients with cancer has been associated with decreased incidence of gram-negative bacteremia. Bacterial antimicrobial resistance is likely to cause a progressive lack of efficacy of fluoroquinolones, but no convincing evidence from clinicoepidemiologic observations has proved this hypothesis.
led to an increase in the incidence of resistance to these agents [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , which has limited their clinical efficacy. In 1988, the incidence of fluoroquinolone-resistant bacteria causing bacteremia in patients with acute leukemia was !0.5%, but this incidence rose significantly during the following years, as has been documented by various health care centers, including the University Hospital of Ulm (Ulm, Germany) [9, 10] . Furthermore, the emergence of cross-resistance to fluoroquinolones and unrelated classes of antibiotics [9, 10, [17] [18] [19] has become a major concern. Consequently, the routine practice of administering antimicrobial prophylaxis to patients with neutropenia has been questioned repeatedly [20] [21] [22] [23] [24] [25] [26] . Two large meta-analyses were unable to pro-vide evidence for a reduction of infection-related mortality among patients receiving fluoroquinolone prophylaxis [1, 27] . Some studies have concluded that prophylaxis could be abandoned safely in areas with a high prevalence of fluoroquinoloneresistant enterobacteria, resulting in less resistance [28] , and the 2002 guidelines from the Infectious Diseases Society of America recommended that routine fluoroquinolone prophylaxis during neutropenia should be avoided [29] .
At the University Hospital of Ulm, fluoroquinolone prophylaxis has been used during neutropenia for many years. At this hospital, an earlier experience with the discontinuation of routine fluoroquinolone prophylaxis in patients with acute leukemia did not yield unequivocal results [30] ; therefore, fluoroquinolone prophylaxis was continued as the standard of care and has included levofloxacin since 1998. In the present study, we reassessed the relationship between fluoroquinolone prophylaxis, morbidity, and the development of resistance by prospective surveillance of infection during periods when prophylaxis was given and periods when it was not given.
METHODS

Study design.
This was a prospective, observational study of inpatients with leukemia, lymphoma, multiple myeloma, aplastic anemia, solid tumors, or amyloidosis who were admitted to the Department of Hematology, Oncology, Rheumatology, and Infectious Diseases at the University Hospital of Ulm. Inclusion criteria were occurrence of neutropenia after chemotherapy (defined as an absolute leukocyte count of !1000 cells/ mL) and an expected duration of neutropenia of у5 days. Patients undergoing allogeneic stem-cell transplantation were excluded. All patients were observed from the first day of neutropenia until 2 days after reconstitution. Patients with consecutive neutropenic episodes could be included more than once. For all patients with fever (defined as single instance of a temperature у38.5ЊC or 2 instances of a temperature increase to 138ЊC) or clinical symptoms suggestive of an infection, blood samples for culture were drawn peripherally, as well as from central venous lines. Further samples for microbiological analysis were obtained at the discretion of the physician in charge of the patient (e.g., stool and urine samples, throat swab specimens, biopsy samples). At the onset of fever, piperacillin plus sulbactam (4 g piperacillin plus 1 g sulbactam t.i.d.) were given as the empirical antibiotic treatment, immediately after samples were obtained. IL-8 levels were measured in all patients at the onset of fever; for those with an IL-8 level 12000 pg/mL, netilmicin was added to the treatment [31] . Antimicrobial treatment was continued until the patient experienced 7 days without fever during neutropenia or 3 days without fever after regeneration from neutropenia.
During the first study period (from 1 October 2002 to 30
September 2003), all patients who met the inclusion criteria received prophylaxis with levofloxacin, 500 mg/day, starting on the last day of chemotherapy. All events were recorded prospectively. During the second study period, all patients were to receive no antibacterial prophylaxis during neutropenia. During a third study period, levofloxacin prophylaxis was to be reintroduced. During the second study period, a stringent "stopping rule" was defined in case of statistically significant differences between study periods and was based on (1) transfer to an intensive care unit (ICU) because of infection or (2) death from infection. The study protocol was approved by the ethics committee of the University of Ulm.
Owing to the premature termination of the second study period, after only 3 weeks (between 1 October and 21 October 2003), the third study period (between 22 October 2003 and 21 January 2004) was considered to be a poststudy observational period that was restricted to 3 months. The decision for discontinuation was made by the interdisciplinary committee monitoring the study (consisting of a statistician, infectious disease specialists, microbiologists, and hematologists).
Microbiological analysis. Clinical samples were processed in the Department of Medical Microbiology and Hygiene of the University Hospital of Ulm. MICs were determined with microbroth-dilution assays. Breakpoints were interpreted according to NCCLS criteria [32] . All bacterial isolates were stored at Ϫ80ЊC for additional analysis, if necessary. PFGE was performed as described elsewhere [17] for all fluoroquinoloneresistant Escherichia coli isolates from the first study year. PFGE patterns were interpreted by use of the criteria described by Tenover et al. [33] . Gram-positive organisms isolated from blood cultures were considered to be the relevant cause of bloodstream infection only if they were isolated from 11 pair of blood cultures and had identical resistance patterns.
Statistical analysis. End points were the incidence rates of febrile neutropenia, bacteremia, gram-negative bacteremia, transfer to an ICU, or death during a neutropenic episode. A generalized linear model was used to predict the probability of an event (e.g., febrile neutropenia), with the dependence structure of the data taken into account (GENMOD procedure in the SAS program [SAS Institute], with parameters dist p bin, link p logit, and type p CS). The dependency of the data was assumed, because patients had у1 neutropenic episode during a study period. For the comparison of results between study periods, ORs and 95% CIs were calculated.
RESULTS
In all treatment groups, patient characteristics were similar with regard to age, average duration of neutropenia, and average duration of neutropenic episodes with fever (table 1) .
Observed rates of complications from infection, at baseline. During the baseline period, 15 (4.8%) of 310 patients had gram- Per episode, mean (median) 11 (9) 11 (9) 11 (9) Per episode with fever, mean (median) 13 (11) 12 (10) 13 (11) NOTE. Neutropenia was defined as a leukocyte count of !1000 cells/mL. The no. of underlying conditions correlated with the no. of neutropenic episodes.
negative bacteremia, and 58 (18.7%) had gram-positive bacteremia. Nine patients died during this period. Three deaths were infection related and were due to (1) pneumonia caused by Comamonas species, (2) pulmonary aspergillosis, or (3) fluoroquinolone-resistant E. coli bacteremia. Thus, infectionrelated mortality was 1% (3 of 310 patients) during this period.
Nine patients developed E. coli bacteremia, and fluoroquinolone resistance was present in all isolates (table 2). A total of 15 gram-negative organisms were isolated from blood cultures; of these, 5 showed partial or full resistance to the empirical antibiotic treatment with piperacillin plus sulbactam (4 g piperacillin plus 1 g sulbactam t.i.d.).
Gram-positive bacteria were isolated from cultures of blood from 58 patients during study period 1. Coagulase-negative staphylococci (CNS) were isolated from 47 (81%) of these patients; other organisms isolated included Enterococcus species, Streptococcus oralis, Micrococcus luteus, Stomatococcus mucilaginosus, and Corynebacterium species. In 44 cases, true grampositive bacteremia was assumed (including 23 cases of febrile infection related to a central venous catheter); however, for 14 of these gram-positive bloodstream isolates, contamination of samples could not be excluded, because the isolates were detected only in a single pair of blood culture samples (see Methods).
Observed rates of complications from infection, during subsequent periods. After discontinuation of fluoroquinolone prophylaxis during study period 2, only 9 patients were included; of these patients, 4 (44.4%) had gram-negative bacteremia. E. coli bacteremia was detected in 3 patients; other gram-negative organisms isolated included Klebsiella pneumoniae, Morganella morganii, and Pseudomonas aeruginosa. All isolates were susceptible to fluoroquinolones and to piperacillin plus sulbactam, except for 1 (M. morganii) isolate that was resistant to b-lactams. The 3 cases of K. pneumoniae infection were identified in patients from 3 different hospital wards. Two of the 4 patients with bacteremia died from septic shock, despite the prompt initiation of antibacterial treatment with piperacillin plus sulbactam and netilmicin. A third patient died from fulminant sepsis, but the organism that caused the infection was never isolated. However, the clinical manifestation of severe sepsis and high levels of IL-8 suggested a gram-negative bacterial infection. Thus, infection-related mortality during the period when levofloxacin treatment was stopped was 33.3%. This significant increase in infection-related mortality, when compared with that for study period 1, led to the early discontinuation of study period 2, after observation of only 9 neutropenic episodes.
In study period 2, gram-positive bacteria were isolated from cultures of blood from 3 patients, and all strains were CNS. Patients were treated with 1 g vancomycin iv b.i.d.
During the third study period, 4 patients (5.7%) had proven gram-negative bacteremia. Three of the causative organisms were fully susceptible to piperacillin plus sulbactam. E. coli bacteremia was detected in 2 patients; both E. coli strains were resistant to fluoroquinolones, and both patients survived. One patient died during study period 3, and the death was related to proven invasive aspergillosis. Thus, infection-related mortality was observed in 1 of 70 cases.
Gram-positive bacteremia was found in 12 patients (17.1%) during study period 3, and culture samples from 11 (91.7%) of these patients grew CNS; other organisms included Enterococcus species and M. luteus. In 11 cases, true gram-positive bacteremia was assumed, including 6 cases of infection related to a central venous catheter (see Methods).
Model-predicted probabilities of complications from infection, during neutropenia. In this study, 116 of 188 patients had 11 neutropenic episode during the same study period. Therefore, dependence of the data was assumed and was included in the model used for the statistical analysis. The modelpredicted probabilities (i.e., the point estimates; data not shown) were compared with the raw proportions in table 2. The point estimates for study period 2 were always higher than those for study periods 1 and 3. For several end points, the 95% CIs did not overlap (i.e., for gram-negative bacteremia, transfer to an ICU because of infection, death, and death from infection).
Model-based comparison of study periods. Table 3 presents the ORs and 95% CIs for the comparisons of study period 2 versus period 1 and of study period 2 versus period 3. For E. coli bacteremia, for example, the OR was ∼18 for both comparisons between periods. Thus, the odds of developing E. coli bacteremia were 18-fold higher during study period 2, compared with study periods 1 and 3. For all events, the odds of occurrence was higher during study period 2. For febrile neu- tropenia, bacteremia, and gram-positive bacteremia, the 95% CIs included 1. For all other events, the 95% CIs did not include 1; thus, the differences between periods could be regarded as statistically significant. The observed widths of the 95% CIs were caused by the low number of cases in study period 2. Typing of resistant E. coli isolates. All 9 drug-resistant E. coli isolates from study period 1 were genotyped using PFGE. All but 2 isolates showed divergent PFGE patterns; thus, we did not find evidence of a local outbreak.
DISCUSSION
The scope of our study was to assess the impact of levofloxacin prophylaxis on the drug-susceptibility profiles of gram-negative bacteria and their correlation with clinical outcome, under standard conditions. We describe our experience with the discontinuation of levofloxacin prophylaxis for patients receiving chemotherapy for hematologic malignancies. Initially, we had planned to include 3 study periods of 1-year duration each. Study period 1 included routine levofloxacin prophylaxis and was dedicated to the collection of clinical and microbiological data from the study population. During study period 2, prophylaxis was to be discontinued, to challenge the hypothesis of reversible resistance patterns among Enterobacteriaceae, as has been suggested in a pilot study by Martino et al. [28] . In a third study period, prophylaxis was to be reintroduced into the population, to study the kinetics of the reemergence of fluoroquinolone resistance. Because of the premature discontinuation of study period 2, the third period was shortened to 3 months and was designed to be a poststudy observational period. This period was added in order to exclude bias and to NOTE. For febrile neutropenia, bacteremia, and gram-positive bacteremia, the 95% CIs included 1. For all other events, the 95% CIs did not include 1; therefore, the differences between study periods were considered to be statistically significant. ICU, intensive care unit.
a During study period 1, transfer to the ICU because of infection was not observed; therefore, a model prediction was impossible. The OR for study period 2 vs. period 1 was expected to be higher than the OR for study period 2 vs. period 3, because of the observed incidence rate of infection in study period 3. b Related to a neutropenic episode.
ensure the effectiveness of levofloxacin prophylaxis. The incidences of important end points were similar during study periods 1 and 3 (both levofloxacin prophylaxis periods) (table 2) .
In study period 1, we confirmed the observation of a high proportion of cases of gram-negative bacteremia among these patients, without a significant impact on morbidity and mortality (table 2) [1, 27] . During this first study period, we also noted a high drug-resistance rate among E. coli isolates from cases of bacteremia (9 of 9) and there was 1 death due to E. coli bacteremia.
During the second study period, a dramatic increase in infection-related mortality was observed; consequently, the study was prematurely terminated after 3 weeks. Five episodes of sepsis and/or gram-negative bacteremia, with a fatal outcome in 3 cases, were the immediate cause for discontinuation of the study. This decision was made by the interdisciplinary committee monitoring the study (consisting of a statistician, infectious disease specialists, microbiologists, and hematologists). In study period 2, the risk of various clinical end points was higher than during the periods when prophylaxis was being given (table 3) .
In study period 2, all gram-negative strains isolated (including 3 strains of E. coli) were susceptible to b-lactams, and treatment usually should have been successful. However, the fulminant course of disease led to death in 3 cases (table 2) , despite prompt initiation of treatment with b-lactams and aminoglycosides and intensive medical care. The median time from the beginning of fever until initiation of antibiotic treatment was similar in all study periods (3 h in period 1; 2.3 h in period 2; and 2.2 h in period 3). In study period 2, the severe clinical courses caused by fluoroquinolone-susceptible strains might have been prevented by fluoroquinolone prophylaxis. On the other hand, of the cases of bacteremia caused by strains of fluoroquinolone-resistant E. coli during study period 1, only 1 case was fatal. Reduced virulence of fluoroquinolone-resistant E. coli is a possible explanation for the relatively low case-fatality rate for gram-negative bacteremia during prophylaxis, as has been postulated elsewhere [17, [34] [35] [36] .
Although infection during levofloxacin prophylaxis was always caused by a single agent, cases of gram-negative bacteremia were mostly polymicrobial during study period 2. These findings suggest that levofloxacin may be able to reduce the burden of infectious organisms, thereby minimizing the risk of fulminant courses of infection.
During fluoroquinolone prophylaxis, the incidence of gramnegative bacteremia and infection-related mortality were low, as was observed in a previous study [9] . When fluoroquinolone prophylaxis is discontinued, a higher incidence of gram-negative bacteremia is to be expected, and this expectation was confirmed in the present study by an increase in the incidence rate from 4.8% in study period 1 to 44.4% in study period 2. During study period 3, a low incidence for gram-negative bacteremia was promptly reestablished (5.7%). We showed that levofloxacin effectively prevented infection-related deaths in patients with gram-negative bacteremia during study periods 1 and 3 (mortality, ∼1%). This result is in contrast with the results of the majority of previous studies: although the effect of fluoroquinolone prophylaxis on the incidence rate of gram-negative bacterial infection has been proved repeatedly, most studies have been unable to show an effect on infection-related mortality [1, 27] .
Levofloxacin is also effective against a variety of gram-pos-itive bacteria [5, 6] . The incidence of gram-positive bacteremia was higher during study period 2. Thus, as with gram-negative bacterial bloodstream infection, levofloxacin was effective in reducing the incidence of gram-positive bacteremia. However, none of the cases of bacteremia caused by gram-positive bacterial infection led to death. It is remarkable that, during study period 1, cases of E. coli bacteremia were exclusively caused by fluoroquinolone-resistant strains, whereas, during study period 2, the strains were fluoroquinolone susceptible (table 2) . A similar observation of reemerging fluoroquinolone-susceptible Enterobacteriaceae after discontinuation of prophylaxis was made in 2 previous studies [28, 37] . Because of this fast reemergence of susceptible Enterobacteriaceae, temporary discontinuation of prophylaxis is an appealing approach for the preservation of the long-term effectiveness of fluoroquinolones. Antimicrobial cycling by scheduled discontinuation of specific antibiotics has been effectively used to reduce the prevalence of antimicrobial resistance against single agents [38] .
In our study, patients receiving fluoroquinolone prophylaxis had a survival advantage, compared with patients not receiving prophylaxis. Thus, our data are not in accordance with those from previous studies [28, 37] . The effectiveness of fluoroquinolones was retained, despite high resistance rates among E. coli isolates. Our findings are further supported by those of other studies that showed the continued efficacy of fluoroquinolones in suppressing gram-negative bacterial infections [39, 40] . The efficacy of fluoroquinolone prophylaxis did not appear to decrease in those studies that showed higher rates of antibiotic resistance [1] . The outcome for gram-negative bacteremia remained relatively constant during an 8-year period, despite rising resistance rates [27] , which further supports our claim for continued prophylaxis despite high rates of resistance.
After discontinuation of prophylaxis, a rapid increase in the incidence of susceptible strains was observed; thus, the selection for resistant strains was temporal. Accordingly, reintroduction of prophylaxis led to prompt selection for strains resistant to fluoroquinolones (table 2, study period 3). This rapid emergence of resistant strains after only a few days of prophylaxis has been observed previously by others [10, [41] [42] [43] , and various risk factors associated with emergence of fluoroquinoloneresistant bacilli have been identified, including fluoroquinolone exposure prior to hospitalization or during a hospital stay [44] .
In the present study, we excluded the possibility of significant hospital transmission of E. coli infection. These results further support the assumption that the emergence of fluoroquinolone resistance in E. coli is mostly induced on a polyclonal basis [17] .
Because of the small number of cases observed during study period 2, we may have overestimated the true incidence of gram-negative bacteremia. Without prophylaxis, the incidence of E. coli bacteremia is expected to be 10%-20% [3, 45] . A comparable incidence of E. coli bacteremia during fluoroquinolone prophylaxis would indicate a complete loss of efficacy. In the present study, the proven effectiveness of prophylaxis, as indicated by incidences of !6% for gram-negative bacteremia and !3% for E. coli bacteremia (table 2, study periods 1 and 3), is consistent with the above-mentioned estimates.
Generalization of our results seems to be critical, since we describe our experience at a single center with a limited number of patients. These clinical observations suggest that, despite increasing fluoroquinolone resistance, prophylactic use of levofloxacin had a beneficial impact on infection-related mortality during neutropenia. The incidence of resistant gram-negative bacteremia may vary greatly between regions and institutions. If the observed increase in resistance [7, 9, 10, 43] continues at the same pace, fluoroquinolone prophylaxis may become ineffective in the future. Thus, continued monitoring of the incidence rate of gram-negative bacteremia is warranted for the timely detection of a loss in the efficacy of fluoroquinolone prophylaxis.
